Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07382752 · ClinicalTrials.gov registry record
Decoupling Immunotherapy Toxicity and Cancer Response
A clinical trial of Tumor and Cardiovascular, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 1
- Study location
NCT07382752: Recruiting study of Tumor and Cardiovascular, sponsored by M.D. Anderson Cancer Center.
NCT07382752 is a study of Tumor and Cardiovascular that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,200 participants, above the 118-participant average among 18 other Tumor trials with a reported enrollment target (917% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07382752, a study of Tumor and Cardiovascular, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2030-06-30 |
What NCT07382752 shows while recruiting
NCT07382752 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 118-participant average among 18 other Tumor trials with a reported enrollment target (917% higher).
The record links to 2 conditions, with Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT07382752 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07382752 about?
NCT07382752 is a clinical study titled "Decoupling Immunotherapy Toxicity and Cancer Response". This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
What is the current status of trial NCT07382752?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2026-01-09. Estimated completion is 2030-06-30.
What conditions does trial NCT07382752 study?
This clinical trial studies the following conditions: Tumor, Cardiovascular.
Who is sponsoring clinical trial NCT07382752?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07382752 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07382752's enrollment target sits among peer trials
1,200 1st of 18 higher than 18 of 18 other Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Live Tumor Fragments of Surgical Resections
RECRUITING
-
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI